Home Home Home Inbox Home Search

Event

Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMA/LABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the Real-World Setting: a Claims-Linked Survey Study [Board .

Location: Board no. 611
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Monday
May
21
2:15 PM
4:15 PM

Speaker(s)/Author(s)

Jonathan Kurlander

MS
Optum, Inc.

Eric T. Wittbrodt

Pharm.D., M.P.H.
AstraZeneca

Valery Walker

MS
Optum, Inc.

Maureen Carlyle

MPH
Optum, Inc.

Lauren Millette

Ph.D.
AstraZeneca

Junliang Tong

MS
Optum, Inc.

Michael DePietro

MD
AstraZeneca

View Abstract

Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMA/LABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the .

Parent Sessions

  • B102 - CLINICAL TRIALS AND STUDIES IN COPD...
    05-21-2018 2:15 PM - 4:15 PM
    • Home Home Home Inbox Home Search